Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.84 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.84 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468446 | 0.92 | PIK3CD (0.85) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL393460 | 0.90 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2110747 | 0.90 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL3622849 | 0.89 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL391076 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2466623 | 0.89 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2435469 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2469939 | 0.88 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL393696 | 0.88 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL994929 | 0.88 | PIK3CD (0.78) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812444-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-08-26 | — | — | EP | claimed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | claimed |
| US-8252792-B2 | Pyrimidine derivatives as PI3K inhibitors | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-28 | — | — | US | claimed |
| US-8101607-B2 | Pharmaceutical compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2012-01-24 | — | — | US | claimed |
| US-20100280027-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-04 | — | — | US | claimed |
| US-7776856-B2 | Pharmaceutical compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2010-08-17 | — | — | US | claimed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | claimed |
| US-20090131429-A1 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-21 | — | — | US | claimed |
| EP-1812444-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | claimed |
| WO-2006046035-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | claimed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| EP-1812444-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-08-26 | — | — | EP | disclosed |
| US-20090131429-A1 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-2032582-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007122410-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1812444-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046035-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280027-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3C2B, PIK3C2A | PIK3CD 4/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20090131429-A1 | Pharmaceutical compounds | PIK3CA, PIK3C2B, PIK3CD | PIK3CD 3/4885PIK3CA 1/4885PIK3CB 12/4885 |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 3/4885 |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | TLR9, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3CA 8/4885PIK3CB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.